(Q37667100)

21 August 2017

1 reference

title

Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease (English)

1 reference

chronic obstructive pulmonary disease

21 August 2017

main subject

1 reference

Guy F Joos

1

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 February 2010

1 reference

Expert Opinion on Investigational Drugs

21 August 2017

published in

1 reference

21 August 2017

volume

19

1 reference

21 August 2017

issue

2

1 reference

21 August 2017

page(s)

257-264

1 reference

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543780903505084

Novel long-acting bronchodilators for COPD and asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903505084

Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903505084

Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903505084

The pharmacological properties of tiotropium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903505084

Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903505084

A randomised controlled comparison of tiotropium nd ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903505084

Management of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903505084

Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903505084

Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903505084

A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903505084

Long-term Treatment Benefits With Tiotropium in COPD Patients With and Without Short-term Bronchodilator Responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903505084

Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903505084

Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903505084

A 4-year trial of tiotropium in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903505084

Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903505084

The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903505084

A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903505084

Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903505084

Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903505084

Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903505084

Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903505084

Effects of short-acting bronchodilators added to maintenance tiotropium therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903505084

Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903505084

The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903505084

Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903505084

A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903505084

Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903505084

Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903505084

Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903505084

Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903505084

Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903505084

Emerging inhaled bronchodilators: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903505084

Muscarinic receptors mediate stimulation of human lung fibroblast proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903505084

Muscarinic receptors mediate stimulation of collagen synthesis in human lung fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903505084

10.1517/13543780903505084

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference